Screening for novel antituberculosis agents that are effective against multidrug resistant tuberculosis

Current Topics in Medicinal Chemistry

Volumn 7, Issue 5, 2007, Pages 499-507

  Matsumoto, Makoto ^a   Hashizume, Hiroyuki ^a   Tsubouchi, Hidetsugu ^a   Sasaki, Hirofumi ^a   Itotani, Motohiro ^a   Kuroda, Hideaki ^a   Tomishige, Tatsuo ^a   Kawasaki, Masanori ^a   Komatsu, Makoto ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

BRM test; Mycolic acid; Mycolic acid inhibitor; Nitrodehydroimidazooxazole; Tuberculosis

Indexed keywords

ANTIINFECTIVE AGENT; ETHAMBUTOL; ISONIAZID; LIPID; MYCOLIC ACID; NITROFURAN DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; OPC 37306; OXAZOLE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL STRAIN; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; GENE IDENTIFICATION; INHIBITION KINETICS; LIPOGENESIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MUTAGENICITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE; HUMANS; ISONIAZID; LIPIDS; MYCOLIC ACIDS; TUBERCULOSIS;

EID: 33947661830     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780059727     Document Type: Review

References (22)

1. World Health Organization. Removing Obstacles to Healthy Development, 1999.
2. Dye, C.; Scheels, S.; Dolin, P.; Pathania, V.; Raviglione, M.C. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. JAMA, 1999, 282(7), 677-686.
3. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994; 72, 231-220.
4. World Health Organization. Anti-tuberculosis Drug Resistance in the World, Report No. 2, Prevalence and Trends. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. WHO/CDS/TB/ 2000 278. WHO, Geneva, 2000.
5. Espinal, M.A. The global situation of MDR-TB. Tuberculosis 2003, 83, 44-51.
6. Banerjee, A.; Dubnau, E.; Quemard, A.; Balasubramanian, V.; Um, KS.; Wilson, T.; Collins, D.; de Lisle, G.; Jacobs, W. R. Jr. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994, 263, 227-30.
7. Telenti, A.; Imboden, P.; Marchesi, F.; Lowrie, D.; Cole, S.; Colston, M. J.; Matter, L.; Schopfer, K.; Bodmer, T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993, 341, 647-50.
8. Telenti, A.; Philipp, W.J.; Sreevatsan, S.; Bernasconi, C.; Stockbauer, K.E.; Wieles, B.; Musser, J. M.; Jacobs, W.R. Jr. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat. Med. 1997, 3, 567-70.
9. Nair, J.; Rouse, D.A.; Bai, G.H.; Morris, S.L. The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of Mycobacterium tuberculosis. Mol. Microbiol. 1993, 10, 521-7.
10. Rattan, A.; Kalia, A.; Ahmad, N. Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Emerg. Infect. Dis. 1998, 4, 195-209.
11. Flynn, J.L.; Chan,. J.; Triebold, K.J.; Dalton, D.K.; Stewart, T.A.; Bloom, B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 1993, 178, 2249-2254.
12. Condos, R.; Rom, W.N.; Schluger, N.W. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet. 1997, 349(9064), 1513-1515.
13. Kinjo, Y.; Kawakami, K.; Uezu, K.; Yara, S.; Miyagi, K.; Koguchi, Y.; Hoshino, T.; Okamoto, M.; Kawase, Y.; Yokota, K.; Yoshino, K.; Takeda, K.; Akira, S.; Saito, A. Contribution of IL-18 to Th1 response and host defense against infection by Mycobacterium tuberculosis: a comparative study with IL-12p40. J. Immunol. 2002, 169(1), 323-329.
14. Dohertyl, T.M.; Sher, A. IL-12 Promotes Drug-Induced Clearance of Mycobacterium avium Infection in Mice. J. Immunol. 1998, 160, 5428-5435.
15. Cole, S.T.; Brosch, R.; Parkhill, J.; Garnier, T.; Churcher, C.; Harris, D. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998, 393(6685), 537-44.
16. Yano, I.; Tomiyasu, I.; Kitabatake, S.; Kaneda, K. Granuloma forming activity of mycolic acid-containing glycolipids in Nocardia and related taxa. Acta Leprologica 1984, 2, 341-349.
17. Hamasaki, N.; Isowa, K.; Terano, Y.; Matsumoto, T.; Arakawa, T.; Kuroki, T.; Yano, I. In vivo administration of mycobacterial cord factor (trehalose 6, 6′-dimycolate) can induce lung and liver gramulomas and thymic atrophy in rabbits. Infect Immun. 2000, 68(6), 3704-3709.
18. Yuan, Y.; Crane, D.D.; Barry, C.E. The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth in Mycobacterium tuberculosis. Mol. Microbiol. 1998, 29, 1449-1458.
19. Raether, W. & Häel, H. Nitrohetrocyclic drugs with broad spectrum activity. Parasitol. Res. 2003, 90, S19-S39.
20. Nagarajan, K., Shankar, R. G., Rajappa, S., Shenoy, S. T. & Costa-Pereira, R. Nitroimidazoles XXI 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles with anti-tubercular activity. Eur. J. Med. Chem. 1989, 24, 631-33.
21. Ashtekar, D.R.; Costa-Perira, R.; Nagrajan, K.; Vishvanathan, N.; Bhatt, A.D.; Rittel, W. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1993, 37, 183-186.
22. Edwards, D. I.; Nitroimidazole drugs-action and resistance mechanisms I. Mechanisms of action. J. Antimicrob. Chemoth. 1993, 31, 9-20.